At its recent analyst day, InterMune Inc. updated investors on plans for the confirmatory trial required to obtain U.S. approval for its idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone), which the FDA slapped with a complete response letter last year. Read More
